Seeking Alpha

On January 15, I found it very interesting that the CFO of Teva Pharmaceuticals (TEVA) indicated that Teva had plans to return to a deal making strategy on the same day that Antares Pharma (ATRS) announced the launch of OTREXUP. OTREXUP has a chance to be a transformational product for Antares, since it takes a well established rheumatoid arthritis drug in methotrexate, and changes the delivery method from an oral pill to a self administered subcutaneous injection. Subcutaneous injection not only allows for greater blood levels of medication than oral, but may also cut down on the gastrointestinal side effects from the oral medication. Given that Antares has taken the current standard of care...

Only subscribers can access this article, which is part of the PRO research library covering 3,741 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: